MX2023014695A - Proteinas que unen cd80 y/o cd86 y ox40l. - Google Patents

Proteinas que unen cd80 y/o cd86 y ox40l.

Info

Publication number
MX2023014695A
MX2023014695A MX2023014695A MX2023014695A MX2023014695A MX 2023014695 A MX2023014695 A MX 2023014695A MX 2023014695 A MX2023014695 A MX 2023014695A MX 2023014695 A MX2023014695 A MX 2023014695A MX 2023014695 A MX2023014695 A MX 2023014695A
Authority
MX
Mexico
Prior art keywords
proteins
ox40l
bind
polypeptides
polypeptide
Prior art date
Application number
MX2023014695A
Other languages
English (en)
Spanish (es)
Inventor
Gang Chen
Qi An
Alec Gross
Chia Chi Sun
Yves Fomekong Nanfack
Bijan Zakeri
Qingyong Ji
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2023014695A publication Critical patent/MX2023014695A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2023014695A 2021-06-08 2022-06-07 Proteinas que unen cd80 y/o cd86 y ox40l. MX2023014695A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208478P 2021-06-08 2021-06-08
US202263343268P 2022-05-18 2022-05-18
PCT/US2022/032482 WO2022261079A2 (en) 2021-06-08 2022-06-07 Proteins that bind cd80 and/or cd86, and ox40l

Publications (1)

Publication Number Publication Date
MX2023014695A true MX2023014695A (es) 2024-01-15

Family

ID=84426420

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014695A MX2023014695A (es) 2021-06-08 2022-06-07 Proteinas que unen cd80 y/o cd86 y ox40l.

Country Status (11)

Country Link
US (1) US20240262922A1 (enExample)
EP (1) EP4351644A4 (enExample)
JP (1) JP2024524880A (enExample)
KR (1) KR20240019224A (enExample)
AU (1) AU2022290257A1 (enExample)
BR (1) BR112023025553A2 (enExample)
CA (1) CA3218785A1 (enExample)
IL (1) IL309119A (enExample)
MX (1) MX2023014695A (enExample)
TW (1) TW202315890A (enExample)
WO (1) WO2022261079A2 (enExample)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008007648A1 (fr) * 2006-07-10 2008-01-17 Institute For Antibodies Co., Ltd. Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
US9574002B2 (en) * 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
US20140370012A1 (en) * 2012-01-27 2014-12-18 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
WO2016142768A1 (en) * 2015-03-10 2016-09-15 Eureka Therapeutics, Inc. Ror2 antibody
JP7628764B2 (ja) * 2015-09-29 2025-02-12 アムジエン・インコーポレーテツド Ａｓｇｒ阻害剤
WO2020192709A1 (en) * 2019-03-27 2020-10-01 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific polypeptide complexes

Also Published As

Publication number Publication date
EP4351644A2 (en) 2024-04-17
TW202315890A (zh) 2023-04-16
BR112023025553A2 (pt) 2024-02-20
AU2022290257A1 (en) 2023-11-30
WO2022261079A3 (en) 2023-01-19
AU2022290257A9 (en) 2023-12-14
CA3218785A1 (en) 2022-12-15
EP4351644A4 (en) 2025-04-30
KR20240019224A (ko) 2024-02-14
IL309119A (en) 2024-02-01
WO2022261079A2 (en) 2022-12-15
US20240262922A1 (en) 2024-08-08
JP2024524880A (ja) 2024-07-09

Similar Documents

Publication Publication Date Title
EA202192024A1 (ru) Рецепторы, обеспечивающие прицельную костимуляцию, для адоптивной клеточной терапии
SA519410565B1 (ar) (ctla-4)أجسام مضادة أحادية النسيلة جديدة لبروتين مرتبط بخلية ليمفاوية تائية سامة للخلايا 4
NZ790656A (en) Antibodies and fusion proteins that bind to ccr8 and uses thereof
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
MX2021004059A (es) Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas.
WO2022016112A8 (en) Receptors providing targeted costimulation for adoptive cell therapy
JOP20190248A1 (ar) بروتينات ربط مولد ضد trem2 واستخداماته
WO2020006374A3 (en) Anti-sirp-beta1 antibodies and methods of use thereof
MX2012007318A (es) Proteina de fusion de la region constante del anticuerpo-cd47 tetravalente para usarse en terapia.
AU2018249796A1 (en) Antibody Fc variants for improving blood half-life
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
MX2022007231A (es) Anticuerpos anti-mertk y metodos de uso de los mismos.
NZ785401A (en) Anti-ms4a4a antibodies and methods of use thereof
MX2022013956A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion especificas de cd70.
EP3546481A3 (en) Anti-interleukin 22 (il-22) antibody and uses thereof
MX2025000124A (es) Combinaciones de proteinas de fusion a fc heterodimericas il15/il15r alfa y anticuerpos biespecificos fcrh5xcd3 para el tratamiento de tipos de cancer de sangre
MX2022012021A (es) Peptidos de dominios knob autonomos.
CR20220608A (es) Anticuerpos anti-cd200r1 y métodos de uso de estos
Sapski et al. Tumor-targeted costimulation with antibody-fusion proteins improves bispecific antibody-mediated immune response in presence of immunosuppressive factors
WO2021231741A3 (en) Anti-pd-l1 antibodies and anti-pd-l1/il10 fusion proteins
WO2022261079A3 (en) Proteins that bind cd80 and/or cd86, and ox40l
MX2024001808A (es) Proteinas que desacoplan la citotoxicidad tumoral mediada por celulas t de la liberacion de citoquinas proinflamatorias.
MX2023012300A (es) Anticuerpos humanos contra artemina y metodos de uso de estos.
MX2023007713A (es) Anticuerpos monoclonales novedosos para proteina 4 asociada con el linfocito t citotoxico (ctla-4).
Tokarski et al. Tolerability of Teclistamab and Talquetamab in Relapse/Refractory Multiple Myeloma (RRMM) Patients with Severe Renal Insufficiency: Case Series